Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. The need for new asthma treatments
3. Poor asthma control
4. Asthma treatment (1)
5. Evolution in asthma therapy
6. SMART reduces severe exacerbations
7. Asthma treatment (2)
8. Strategies for new asthma treatments
9. Unmet needs: mild-moderate asthma
10. Unmet needs: severe asthma
11. New bronchodilators
12. Anti-inflammatory approaches
13. Prostaglandin D2 in asthma
14. Targeting cytokines in asthma
15. Mepolizumab in severe eosinophilic asthma
16. Interleukin-13 in asthma
17. IL-4/IL-13 blockade in asthma
18. Anti-TNF in refractory asthma
19. Anti-TNF in severe asthma
20. TSLP and asthma
21. Chemokine antagonists in asthma
22. Dissociation of corticosteroid effects
23. Dissociated corticosteroids
24. New anti-inflammatory treatments
25. PDE4 inhibitors
26. Roflumilast in asthma
27. PDE4 inhibitors: side effects
28. Mast cell inhibitors
29. Corticosteroid insensitivity
30. Reversal of corticosteroid resistance
31. Theophylline and ICS in smoking asmathics
32. Macrolide in neutrophilic asthma
33. A potential cure for asthma
34. Conclusions: new asthma treatments

Topics Covered

• Improvements in existing therapies have been the main approach
• New classes of drug in development
• Upcoming oral and inhaled therapies that target inflammation in asthma
• Patients with severe disease
• Inflammation in severe asthma is usually corticosteroid insensitive

Links

Series:

• Advances in Asthma

Categories:

• Biochemistry
• Cell Biology
• Diseases, Disorders & Treatments
• Immunology
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on December 29, 2011

Financial Disclosures

• Peter Barnes receives research grants from AstraZeneca and Boehringer-Ingelheim and is an advisor and/or gives talks for AstraZeneca, Boehringer-Ingelheim, Covis, Novartis, Pieris and Teva.